SHORT SyndromeSymptoms, Doctors, Treatments, Advances & More
Learn About SHORT Syndrome
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Wataru Ogawa practices practicing medicine in Kobe, Japan. Mr. Ogawa is rated as an Elite expert by MediFind in the treatment of SHORT Syndrome. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Rabson-Mendenhall Syndrome, SHORT Syndrome, Isolated ACTH Deficiency, Gastrectomy, and Sleeve Gastrectomy.
BIDMC Department Of Neurology
Thomas Scammell is a Neurologist and a Sleep Medicine provider practicing medicine in Boston, Massachusetts. Dr. Scammell is rated as a Distinguished provider by MediFind in the treatment of SHORT Syndrome. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Narcolepsy, Drowsiness, Idiopathic Hypersomnia, and SHORT Syndrome. Dr. Scammell is board certified in American Board Of Psychiatry And Neurology.
OSF Medical Group - Primary Care
Justin Holschbach is a primary care provider, practicing in Family Medicine in Bloomington, Illinois. Dr. Holschbach is rated as an Advanced provider by MediFind in the treatment of SHORT Syndrome. He is also highly rated in 45 other conditions, according to our data. His clinical expertise encompasses Low Sodium Level, Peptic Ulcer, Necrosis, and Colorectal Cancer. Dr. Holschbach is board certified in American Board Of Family Medicine.
Summary: Genetic lipodystrophy syndromes are extremely rare, orphan diseases with overall estimated prevalence of less than 2,000 in the United States. These rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications diabetes, dyslipidemia and hepatic steatosis. Due to these metabolic problems, atherosclerotic vascular disease, ...
Summary: This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SBS-associated intestinal failure (SBS-IF).